Dexibuprofen biodegradable nanoparticles: one step closer towards a better ocular interaction study

dc.contributor.authorSánchez-López, E. (Elena)
dc.contributor.authorEsteruelas Navarro, Gerard
dc.contributor.authorOrtiz Rodrigo, Alba
dc.contributor.authorEspina García, Marta
dc.contributor.authorPrat Aixelà, Josefa
dc.contributor.authorMuñoz Juncosa, Montserrat
dc.contributor.authorCano Fernández, Amanda
dc.contributor.authorCalpena Campmany, Ana Cristina
dc.contributor.authorEttcheto Arriola, Miren
dc.contributor.authorCamins Espuny, Antoni
dc.contributor.authorAlsafi, Zaid
dc.contributor.authorSouto, Eliana B.
dc.contributor.authorGarcía López, María Luisa
dc.contributor.authorPujol Cubells, Montserrat
dc.date.accessioned2020-06-18T09:01:41Z
dc.date.available2020-06-18T09:01:41Z
dc.date.issued2020-04-10
dc.date.updated2020-06-18T09:01:41Z
dc.description.abstractOcular inflammation is one of the most prevalent diseases in ophthalmology, which can affect various parts of the eye or the surrounding tissues. Non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, are commonly used to treat ocular inflammation in the form of eye-drops. However, their bioavailability in ocular tissues is very low (less than 5%). Therefore, drug delivery systems such as biodegradable polymeric PLGA nanoparticles constitute a suitable alternative to topical eye administration, as they can improve ocular bioavailability and simultaneously reduce drug induced side effects. Moreover, their prolonged drug release can enhance patient treatment adherence as they require fewer administrations. Therefore, several formulations of PLGA based nanoparticles encapsulating dexibuprofen (active enantiomer of Ibuprofen) were prepared using the solvent displacement method employing different surfactants. The formulations have been characterized and their interactions with a customized lipid corneal membrane model were studied. Ex vivo permeation through ocular tissues and in vivo anti-inflammatory efficacy have also been studied.
dc.format.extent24 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec702031
dc.identifier.issn2079-4991
dc.identifier.pmid32290252
dc.identifier.urihttps://hdl.handle.net/2445/166211
dc.language.isoeng
dc.publisherMDPI
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/nano10040720
dc.relation.ispartofNanomaterials, 2020, vol. 10, num. 4, art. 720
dc.relation.urihttps://doi.org/10.3390/nano10040720
dc.rightscc-by (c) Sánchez-López E. et al., 2020
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es
dc.sourceArticles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)
dc.subject.classificationSistemes d'alliberament de medicaments
dc.subject.classificationAgents antiinflamatoris
dc.subject.classificationOftalmopaties
dc.subject.otherDrug delivery systems
dc.subject.otherAntiinflammatory agents
dc.subject.otherOphthalmopathies
dc.titleDexibuprofen biodegradable nanoparticles: one step closer towards a better ocular interaction study
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
702031.pdf
Mida:
5.32 MB
Format:
Adobe Portable Document Format